Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes
Abstract Background This study evaluates the efficacy of intravitreal Faricimab in reducing pigment epithelium detachment (PED) and fluid volumes in both treatment-naïve eyes and eyes unresponsive to anti-VEGF mono-therapies, all diagnosed with type 1 macular neovascularization (T1 MNV) over a perio...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | International Journal of Retina and Vitreous |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40942-025-00629-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544473640697856 |
|---|---|
| author | Jennifer Cattaneo Paolo Forte Giovanni Forte Chiara M. Eandi |
| author_facet | Jennifer Cattaneo Paolo Forte Giovanni Forte Chiara M. Eandi |
| author_sort | Jennifer Cattaneo |
| collection | DOAJ |
| description | Abstract Background This study evaluates the efficacy of intravitreal Faricimab in reducing pigment epithelium detachment (PED) and fluid volumes in both treatment-naïve eyes and eyes unresponsive to anti-VEGF mono-therapies, all diagnosed with type 1 macular neovascularization (T1 MNV) over a period of 12-month. Methods A retrospective, single-center cohort study was conducted at the Jules Gonin Eye Hospital, Lausanne, Switzerland. Clinical records of treatment-naïve and non-responder switch patients presenting T1 MNV secondary to neovascular age-related macular degeneration (nAMD) from September 2022 to March 2023 were reviewed. Patients received a loading dose of three monthly Faricimab injections followed by a treat-and-extend (T&E) regimen. Multimodal imaging, including structural OCT and AI-assisted analysis, was used to quantify PED volumes and related fluid biomarkers at baseline, 3-month, 6-month, and 12-month follow-up. Statistical analyses included linear mixed models to evaluate differences and trends in intraretinal (IRF), subretinal fluid (SRF) and PED volumes. Results 65 eyes of 65 patients were enrolled (female: 70.7%; mean age = 80.7yrs, SD = 6.9yrs). 80% had received anti-VEGF treatment (Switch group) and 20% were treatment-Naïve at baseline. At 12 months, intravitreal treatments were more frequent in the Switch group (mean number = 8.3 vs. 6.0; p = 0.009). BCVA improved at the 12-month follow-up in Naïve eyes (+ 6.9 ETDRS letters from baseline, p = 0.053) and was maintained in Switch eyes. No cases of intraocular inflammation were observed. Significant reduction in SRF and IRF volumes were noted in both groups. A significant reduction in PED volume was observed over the follow-up period in both groups (mean slope = -206 nL, 95%CL = -273/-138; p-value < 0.001). Conclusions Intravitreal Faricimab significantly reduced PED volumes in both treatment-Naïve and non-responder Switch patients over 12 months. The study highlights Faricimab’s potential as an effective treatment option for T1 MNV in nAMD, offering significant improvements in PED volume and related fluid biomarkers. |
| format | Article |
| id | doaj-art-e55e497bf9dd4c089df389af93b3aadd |
| institution | Kabale University |
| issn | 2056-9920 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | International Journal of Retina and Vitreous |
| spelling | doaj-art-e55e497bf9dd4c089df389af93b3aadd2025-01-12T12:34:16ZengBMCInternational Journal of Retina and Vitreous2056-99202025-01-0111111110.1186/s40942-025-00629-wFaricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyesJennifer Cattaneo0Paolo Forte1Giovanni Forte2Chiara M. Eandi3Fondation Asile des Aveugles, Department of Ophthalmology, Jules-Gonin Eye Hospital, University of LausanneFondation Asile des Aveugles, Department of Ophthalmology, Jules-Gonin Eye Hospital, University of LausanneSchool of Medicine, University of PaviaFondation Asile des Aveugles, Department of Ophthalmology, Jules-Gonin Eye Hospital, University of LausanneAbstract Background This study evaluates the efficacy of intravitreal Faricimab in reducing pigment epithelium detachment (PED) and fluid volumes in both treatment-naïve eyes and eyes unresponsive to anti-VEGF mono-therapies, all diagnosed with type 1 macular neovascularization (T1 MNV) over a period of 12-month. Methods A retrospective, single-center cohort study was conducted at the Jules Gonin Eye Hospital, Lausanne, Switzerland. Clinical records of treatment-naïve and non-responder switch patients presenting T1 MNV secondary to neovascular age-related macular degeneration (nAMD) from September 2022 to March 2023 were reviewed. Patients received a loading dose of three monthly Faricimab injections followed by a treat-and-extend (T&E) regimen. Multimodal imaging, including structural OCT and AI-assisted analysis, was used to quantify PED volumes and related fluid biomarkers at baseline, 3-month, 6-month, and 12-month follow-up. Statistical analyses included linear mixed models to evaluate differences and trends in intraretinal (IRF), subretinal fluid (SRF) and PED volumes. Results 65 eyes of 65 patients were enrolled (female: 70.7%; mean age = 80.7yrs, SD = 6.9yrs). 80% had received anti-VEGF treatment (Switch group) and 20% were treatment-Naïve at baseline. At 12 months, intravitreal treatments were more frequent in the Switch group (mean number = 8.3 vs. 6.0; p = 0.009). BCVA improved at the 12-month follow-up in Naïve eyes (+ 6.9 ETDRS letters from baseline, p = 0.053) and was maintained in Switch eyes. No cases of intraocular inflammation were observed. Significant reduction in SRF and IRF volumes were noted in both groups. A significant reduction in PED volume was observed over the follow-up period in both groups (mean slope = -206 nL, 95%CL = -273/-138; p-value < 0.001). Conclusions Intravitreal Faricimab significantly reduced PED volumes in both treatment-Naïve and non-responder Switch patients over 12 months. The study highlights Faricimab’s potential as an effective treatment option for T1 MNV in nAMD, offering significant improvements in PED volume and related fluid biomarkers.https://doi.org/10.1186/s40942-025-00629-wType 1 macular neovascularizationType 1 MNVPigment epithelium detachmentPEDFaricimabIntravitreal injection |
| spellingShingle | Jennifer Cattaneo Paolo Forte Giovanni Forte Chiara M. Eandi Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes International Journal of Retina and Vitreous Type 1 macular neovascularization Type 1 MNV Pigment epithelium detachment PED Faricimab Intravitreal injection |
| title | Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes |
| title_full | Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes |
| title_fullStr | Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes |
| title_full_unstemmed | Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes |
| title_short | Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes |
| title_sort | faricimab efficacy in type 1 macular neovascularization ai assisted quantification of pigment epithelium detachment ped volume reduction over 12 months in naive and switch eyes |
| topic | Type 1 macular neovascularization Type 1 MNV Pigment epithelium detachment PED Faricimab Intravitreal injection |
| url | https://doi.org/10.1186/s40942-025-00629-w |
| work_keys_str_mv | AT jennifercattaneo faricimabefficacyintype1macularneovascularizationaiassistedquantificationofpigmentepitheliumdetachmentpedvolumereductionover12monthsinnaiveandswitcheyes AT paoloforte faricimabefficacyintype1macularneovascularizationaiassistedquantificationofpigmentepitheliumdetachmentpedvolumereductionover12monthsinnaiveandswitcheyes AT giovanniforte faricimabefficacyintype1macularneovascularizationaiassistedquantificationofpigmentepitheliumdetachmentpedvolumereductionover12monthsinnaiveandswitcheyes AT chiarameandi faricimabefficacyintype1macularneovascularizationaiassistedquantificationofpigmentepitheliumdetachmentpedvolumereductionover12monthsinnaiveandswitcheyes |